A BILL 
To establish a program to develop antimicrobial innovations 
targeting the most challenging pathogens and most 
threatening infections. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pioneering Anti-
4
microbial Subscriptions To End Up surging Resistance 
5
Act of 2021’’ or the ‘‘PASTEUR Act of 2021’’. 
6
20:39 Jul 22, 2021
H3932
2 
•HR 3932 IH
SEC. 2. DEVELOPING ANTIMICROBIAL INNOVATIONS. 
1
Title III of the Public Health Service Act (42 U.S.C. 
2
241 et seq.) is amended by adding at the end the fol-
3
lowing: 
4
‘‘PART W—DEVELOPING ANTIMICROBIAL 
5
INNOVATIONS 
6
‘‘SEC. 399OO. ESTABLISHMENT OF COMMITTEE; SUBSCRIP-
7
TION MODEL; ADVISORY GROUP. 
8
‘‘(a) IN GENERAL.—Not later than 60 days after the 
9
date of enactment of this part, the Secretary shall estab-
10
lish a Committee on Critical Need Antimicrobials and ap-
11
point members to the Committee. 
12
‘‘(b) MEMBERS.— 
13
‘‘(1) IN GENERAL.—The Committee shall con-
14
sist of at least one representative from each of the 
15
National Institute of Allergy and Infectious Dis-
16
eases, the Centers for Disease Control and Preven-
17
tion, the Biomedical Advanced Research and Devel-
18
opment Authority, the Food and Drug Administra-
19
tion, the Centers for Medicare & Medicaid Services, 
20
the Veterans Health Administration, and the De-
21
partment of Defense. 
22
‘‘(2) CHAIR.—The Secretary shall appoint one 
23
of the members of the Committee to serve as the 
24
Chair of the Committee. 
25
20:39 Jul 22, 2021
H3932
3 
•HR 3932 IH
‘‘(c) DUTIES.—Not later than 1 year after the ap-
1
pointment of all initial members of the Committee, the 
2
Secretary, in collaboration with the Committee, and in 
3
consultation with the Critical Need Antimicrobials Advi-
4
sory Group established under subsection (g), shall do the 
5
following: 
6
‘‘(1) Develop a list of infections for which new 
7
antimicrobial drug development is needed, taking 
8
into account organisms, sites of infection, and type 
9
of infections for which there is an unmet medical 
10
need, findings from the most recent report entitled 
11
‘Antibiotic Resistance Threats in the United States’ 
12
issued by the Centers for Disease Control and Pre-
13
vention, or an anticipated unmet medical need, in-
14
cluding a potential global health security threat. For 
15
the list developed under this paragraph, the Sec-
16
retary, in collaboration with the Committee, may use 
17
the infection list in such most recent report for up 
18
to 3 years following the date of enactment of this 
19
part and subsequently update the list under this 
20
paragraph in accordance with subsection (e). 
21
‘‘(2) Develop regulations, in accordance with 
22
subsection (d), outlining favored characteristics of 
23
critical need antimicrobial drugs, that are evidence 
24
based, clinically focused, and designed to treat the 
25
20:39 Jul 22, 2021
H3932
4 
•HR 3932 IH
infections described in paragraph (1), and estab-
1
lishing criteria for how each such characteristic will 
2
adjust the monetary value of a subscription contract 
3
awarded under subsection (f) or section 399QQ. The 
4
favored characteristics shall be weighed for purposes 
5
of such monetary value such that meeting certain 
6
characteristics, or meeting more than one such char-
7
acteristic, increases the monetary value. Such fa-
8
vored characteristics of an antimicrobial drug shall 
9
include— 
10
‘‘(A) treating infections on the list under 
11
paragraph (1); 
12
‘‘(B) improving clinical outcomes for pa-
13
tients with multi-drug-resistant infections; 
14
‘‘(C) being a first-approved antimicrobial 
15
drug that has the potential to address unmet 
16
medical needs for the treatment of a serious or 
17
life-threatening infection, and, to a lesser ex-
18
tent, second and third drugs that treat such in-
19
fections; 
20
‘‘(D) route of administration, especially 
21
through oral administration; 
22
‘‘(E)(i) containing no active moiety (as de-
23
fined by the Secretary in section 314.3 of title 
24
21, Code of Federal Regulations (or any suc-
25
20:39 Jul 22, 2021
H3932
5 
•HR 3932 IH
cessor regulations)) that has been approved in 
1
any other application under section 505(b) of 
2
the Federal Food, Drug, and Cosmetic Act or 
3
intending to be the subject of a new original 
4
biologics license application under section 
5
351(a); 
6
‘‘(ii) being a member of a new class of 
7
drugs with a novel target and novel mode of ac-
8
tion that are distinctly different from the target 
9
or mode of any antimicrobial drug approved 
10
under section 505 of such Act or licensed under 
11
section 351, including reduced toxicity; 
12
‘‘(iii) not being affected by cross-resistance 
13
to any antimicrobial drug approved under such 
14
section 505 or licensed under such section 351; 
15
‘‘(F) addressing a multi-drug resistant in-
16
fection through a novel chemical scaffold or 
17
mechanism of action; 
18
‘‘(G) having received a transitional sub-
19
scription contract under subsection (f); and 
20
‘‘(H) any other characteristic the Sec-
21
retary, in collaboration with the Committee, de-
22
termines necessary. 
23
‘‘(d) REGULATIONS.— 
24
20:39 Jul 22, 2021
H3932
6 
•HR 3932 IH
‘‘(1) IN GENERAL.—Not later than 1 year after 
1
the appointment of the initial members of the Com-
2
mittee, the Secretary shall issue proposed regula-
3
tions which shall include— 
4
‘‘(A) a process by which the sponsors can 
5
apply for an antimicrobial drug to become a 
6
critical need antimicrobial drug under section 
7
399PP; 
8
‘‘(B) how subscription contracts under 
9
such section shall be established and paid; 
10
‘‘(C) the favored characteristics under sub-
11
section (c)(2), how such characteristics will be 
12
weighed, and the minimum number and kind of 
13
favored characteristics needed for an anti-
14
microbial drug to be designated a critical need 
15
antimicrobial drug; and 
16
‘‘(D) other elements of the subscription 
17
contract process, in accordance with this part. 
18
‘‘(2) 
DEVELOPMENT
OF
FINAL
REGULA-
19
TIONS.—Before finalizing the regulations under 
20
paragraph (1), the Secretary shall solicit public com-
21
ment and hold public meetings for the period begin-
22
ning on the date on which the proposed regulations 
23
are issued and ending on the date that is 120 days 
24
after such date of issuance. The Secretary shall fi-
25
20:39 Jul 22, 2021
H3932
7 
•HR 3932 IH
nalize and publish such regulations not later than 
1
120 days after the close of such period of public 
2
comment and meetings. 
3
‘‘(3) SUBSCRIPTION
CONTRACT
OFFICE.—Not 
4
later than 6 months after the date of enactment of 
5
this part, the Secretary shall propose an agency or 
6
office in the Department of Health and Human 
7
Services to manage the establishment and payment 
8
of subscription contracts awarded under section 
9
399QQ, including eligibility, requirements, and con-
10
tract amounts. The Secretary shall solicit public 
11
comment and finalize the agency or office no later 
12
than 45 days following the proposed agency or of-
13
fice. Such agency or office shall be referred to as the 
14
‘Subscription Contract Office’. 
15
‘‘(e) LIST OF INFECTIONS.—The Secretary, in col-
16
laboration with the Committee, shall update the list of in-
17
fections under subsection (c)(1) at least every 2 years. 
18
‘‘(f) TRANSITIONAL SUBSCRIPTION CONTRACTS.— 
19
‘‘(1) IN GENERAL.—Not earlier than 30 days 
20
after the date of enactment of this part and ending 
21
on the date that the Secretary finalizes the subscrip-
22
tion contract regulations under subsection (d), the 
23
Secretary may use up to $1,000,000,000 of the 
24
amount appropriated under section 399SS(a) to en-
25
20:39 Jul 22, 2021
H3932
8 
•HR 3932 IH
gage in transitional subscription contracts of up to 
1
3 years in length with antimicrobial developers, as 
2
determined by the Secretary, that have developed 
3
antimicrobial drugs treating infections listed in the 
4
most recent report entitled ‘Antibiotic Resistance 
5
Threats in the United States’ issued by the Centers 
6
for Disease Control and Prevention, and may include 
7
antimicrobial drugs that are qualified infectious dis-
8
ease products (as defined in section 505E(g) of the 
9
Federal Food, Drug, and Cosmetic Act), innovative 
10
biological products, or innovative drugs that achieve 
11
a clinical outcome through immunomodulation. Such 
12
a contract may authorize the contractor to use funds 
13
made available under the contract for completion of 
14
postmarketing clinical studies, manufacturing, and 
15
other preclinical and clinical efforts. 
16
‘‘(2) REQUIREMENTS.— 
17
‘‘(A) 
IN
GENERAL.—The 
Secretary, 
18
through the office described in paragraph (4), 
19
may enter into a contract under paragraph 
20
(1)— 
21
‘‘(i) if the Secretary determines that 
22
the antimicrobial drug is intended to treat 
23
an infection for which there is an unmet 
24
20:39 Jul 22, 2021
H3932
9 
•HR 3932 IH
clinical need, an anticipated clinical need, 
1
or drug resistance; 
2
‘‘(ii) subject to terms including— 
3
‘‘(I) that the Secretary shall 
4
cease any payment installments under 
5
a transitional subscription contract if 
6
the sponsor does not— 
7
‘‘(aa) ensure commercial and 
8
Federal availability of the anti-
9
microbial drug within 30 days of 
10
receiving first payment under the 
11
contract; 
12
‘‘(bb) identify, track, and 
13
publicly report drug resistance 
14
data and trends using available 
15
data related to the antimicrobial 
16
drug; 
17
‘‘(cc) develop and implement 
18
education and communications 
19
strategies, including communica-
20
tions for individuals with limited 
21
English proficiency and individ-
22
uals with disabilities, for health 
23
care professionals and patients 
24
20:39 Jul 22, 2021
H3932
10 
•HR 3932 IH
about appropriate use of the 
1
antimicrobial drug; 
2
‘‘(dd) submit a plan for reg-
3
istering the antimicrobial drug in 
4
additional countries where an 
5
unmet medical need exists, which 
6
such plan may be consistent with 
7
the Stewardship and Access Plan 
8
(SAP) 
Development 
Guide 
9
(2021); 
10
‘‘(ee) subject to subpara-
11
graph (B), ensure a reliable drug 
12
supply chain, thus leading to an 
13
interruption of the supply of the 
14
antimicrobial drug in the United 
15
States for more than 60 days; or 
16
‘‘(ff) 
make 
meaningful 
17
progress toward completion of 
18
Food and Drug Administration- 
19
required postmarketing studies, 
20
including such studies that are 
21
evidence based; and 
22
‘‘(II) other terms as determined 
23
by the Secretary; and 
24
‘‘(iii) if— 
25
20:39 Jul 22, 2021
H3932
11 
•HR 3932 IH
‘‘(I) a phase 3 clinical study has 
1
been initiated for the antimicrobial 
2
drug; or 
3
‘‘(II) the antimicrobial drug has 
4
been approved under section 505(c) of 
5
the Federal Food, Drug, and Cos-
6
metic Act or licensed under section 
7
351(a). 
8
‘‘(B) WAIVER.—The requirement under 
9
subparagraph (A)(ii)(I)(ee) may be waived in 
10
the case that an emergency prohibits access to 
11
a reliable drug supply chain. 
12
‘‘(3) TRANSITIONAL
GUIDANCE.—Not later 
13
than 120 days after the appointment of the initial 
14
members of the Committee, the Secretary shall 
15
issue, in consultation with the Committee, transi-
16
tional guidance outlining the antimicrobial drugs 
17
that are eligible for transitional subscription con-
18
tracts under paragraph (1), the requirements to 
19
enter into a transitional subscription contract under 
20
paragraph (2), and the process by which drug devel-
21
opers can enter into transitional subscription con-
22
tracts with the Secretary under this subsection. 
23
‘‘(4) PAYMENT OFFICE AND MECHANISM.—Not 
24
later than 30 days after the date of enactment of 
25
20:39 Jul 22, 2021
H3932
12 
•HR 3932 IH
this part, the Secretary shall determine the agency 
1
or office in the Department of Health and Human 
2
Services that will manage the transitional subscrip-
3
tion contracts, including eligibility, requirements, 
4
and contract amounts, during the period described 
5
in paragraph (1). 
6
‘‘(g) CRITICAL NEED ANTIMICROBIAL ADVISORY 
7
GROUP.— 
8
‘‘(1) IN
GENERAL.—Not later than 30 days 
9
after the appointment of all initial members of the 
10
Committee, the Secretary, in collaboration with the 
11
Committee, shall establish a Critical Need Anti-
12
microbial Advisory Group (referred to in this sub-
13
section as the ‘Advisory Group’) and appoint mem-
14
bers to the Advisory Group. 
15
‘‘(2) MEMBERS.—The members of the Advisory 
16
Group shall include— 
17
‘‘(A) not fewer than 6 individuals who 
18
are— 
19
‘‘(i) infectious disease specialists; or 
20
‘‘(ii) other health experts with exper-
21
tise in researching antimicrobial resistance, 
22
health economics, or commercializing anti-
23
microbial drugs; and 
24
‘‘(B) not fewer than 5 patient advocates. 
25
20:39 Jul 22, 2021
H3932
13 
•HR 3932 IH
‘‘(3) CHAIR.—The Secretary shall appoint one 
1
of the members of the Advisory Group to serve as 
2
the Chair. 
3
‘‘(4) CONFLICTS OF INTEREST.—In appointing 
4
members under paragraph (2), the Secretary shall 
5
ensure that no member receives compensation in any 
6
manner from a commercial or for-profit entity that 
7
develops antimicrobials or that might benefit from 
8
antimicrobial development. 
9
‘‘(5) APPLICABILITY OF FACA.—Except as oth-
10
erwise provided in this subsection, the Federal Advi-
11
sory Committee Act shall apply to the Advisory 
12
Group. 
13
‘‘SEC. 399PP. CRITICAL NEED ANTIMICROBIAL DRUG APPLI-
14
CATION AND PAYMENT THROUGH SUBSCRIP-
15
TION CONTRACTS. 
16
‘‘(a) IN GENERAL.— 
17
‘‘(1) SUBMISSION OF REQUEST.—The sponsor 
18
of an application under section 505(b) of the Fed-
19
eral Food, Drug, and Cosmetic Act or section 351(a) 
20
for an antimicrobial drug may request that the Sec-
21
retary designate the drug as a critical need anti-
22
microbial. A request for such designation may be 
23
submitted after the Secretary grants for such drug 
24
an investigational new drug exemption under section 
25
20:39 Jul 22, 2021
H3932
14 
•HR 3932 IH
505(i) of the Federal Food, Drug, and Cosmetic Act 
1
or section 351(a)(3), and shall be submitted not 
2
later than 5 years after the date of approval under 
3
section 505(c) of the Federal Food, Drug, and Cos-
4
metic Act or licensure under section 351(a). 
5
‘‘(2) CONTENT OF REQUEST.—A request under 
6
paragraph (1) shall include information, such as 
7
clinical, preclinical and postmarketing data, a list of 
8
the favorable characteristics described in section 
9
399OO(c)(2), and any other material that the Sec-
10
retary in consultation with the Committee requires. 
11
‘‘(3) REVIEW BY SECRETARY.—The Secretary 
12
shall promptly review all requests for designation 
13
submitted under this subsection, assess all required 
14
application components, and determine if the anti-
15
microbial drug is likely to meet the favorable charac-
16
teristics identified in the application upon the com-
17
pletion of clinical development. After review, the Sec-
18
retary shall approve or deny each request for des-
19
ignation not later than 90 days after receiving a re-
20
quest. If the Secretary approves a request, it shall 
21
publish the value of the contract that the critical 
22
need antimicrobial developer would be eligible to re-
23
ceive if such developer successfully demonstrates 
24
20:39 Jul 22, 2021
H3932
15 
•HR 3932 IH
that the drug meets the maximum value of the fa-
1
vored characteristics listed in the application. 
2
‘‘(4) LENGTH
OF
DESIGNATION
PERIOD.—A 
3
designation granted under this section shall be in ef-
4
fect for a period of 10 years after the date that the 
5
designation is approved, and shall remain in effect 
6
for such period even if the infection treated by such 
7
drug is later removed from the list of infections 
8
under section 399OO(c)(1). 
9
‘‘(5) SUBSEQUENT REVIEWS.—No sooner than 
10
2 years after a designation approval or denial under 
11
subsection (3), the sponsor may request a subse-
12
quent review to re-evaluate the value of a contract 
13
to include any new information. 
14
‘‘(b) DEVELOPMENT OF DESIGNATED DRUGS.—If a 
15
critical need antimicrobial designation is granted during 
16
clinical development of an antimicrobial drug, the Sec-
17
retary may work with the sponsor to maximize the oppor-
18
tunity for the sponsor to successfully demonstrate that the 
19
antimicrobial drug possesses the favored characteristics of 
20
high-monetary valued products identified under section 
21
399OO(c)(2). 
22
‘‘(c) APPROPRIATE USE OF CRITICAL NEED ANTI-
23
MICROBIAL.— 
24
20:39 Jul 22, 2021
H3932
16 
•HR 3932 IH
‘‘(1) IN GENERAL.—The sponsor of an anti-
1
microbial drug that receives designation under sub-
2
section (a) shall within 90 days of such designation, 
3
submit to the Secretary a plan for appropriate use 
4
of diagnostics, in order for the Secretary and Com-
5
mittee to consider such plan in developing clinical 
6
guidelines. An appropriate use plan— 
7
‘‘(A) shall include— 
8
‘‘(i) the appropriate use of the drug; 
9
and 
10
‘‘(ii) the appropriate use of diagnostic 
11
tools, where available, such as diagnostic 
12
testing for biomarkers related to anti-
13
microbial-resistant pathogens, or other tar-
14
geted diagnostic approaches, to inform use 
15
of the drug; and 
16
‘‘(B) may be developed in partnership with 
17
the Secretary, infectious disease experts, diag-
18
nostic experts or developers, laboratory experts, 
19
or another entity. 
20
‘‘(2) CONSULTATION.—The Secretary shall con-
21
sult with relevant professional societies and the Crit-
22
ical Need Antimicrobial Advisory Group established 
23
under section 399OO(g) to ensure that clinical 
24
guidelines issued by the Secretary under paragraph 
25
20:39 Jul 22, 2021
H3932
17 
•HR 3932 IH
(3), with respect to an antimicrobial drug designated 
1
under subsection (a), includes the use of appropriate 
2
diagnostic approaches, taking into consideration the 
3
diagnostic plan submitted by a sponsor under para-
4
graph (1). 
5
‘‘(3) PUBLICATION OF CLINICAL GUIDELINES.— 
6
Not later than 1 year after the Secretary makes the 
7
first designation under subsection (a), and not less 
8
than every 3 years thereafter, the Secretary shall 
9
publish clinical guidelines in consultation with rel-
10
evant professional societies with respect to each anti-
11
microbial drug that has been approved or licensed as 
12
described in subsection (a)(1) and that has been des-
13
ignated under subsection (a), which guidelines shall 
14
set forth the evidence-based recommendations for 
15
prescribing the drug, in accordance with the submis-
16
sions of the sponsor under paragraph (1) and after 
17
consultation under paragraph (2), as appropriate. 
18
‘‘SEC. 399QQ. SUBSCRIPTION CONTRACTS. 
19
‘‘(a) APPLICATION
FOR
A
SUBSCRIPTION
CON-
20
TRACT.— 
21
‘‘(1) SUBMISSION OF APPLICATIONS.—After ap-
22
proval under section 505(c) of the Federal Food, 
23
Drug, and Cosmetic Act or licensure under section 
24
351(a), the sponsor of an antimicrobial drug des-
25
20:39 Jul 22, 2021
H3932
18 
•HR 3932 IH
ignated as a critical need antimicrobial under section 
1
399PP may submit an application for a subscription 
2
contract with the Secretary, under a procedure es-
3
tablished by the Secretary. 
4
‘‘(2) REVIEW
OF
APPLICATIONS.—The Sec-
5
retary shall, in consultation with the Committee— 
6
‘‘(A) review all applications for subscrip-
7
tion contracts under paragraph (1) and assess 
8
all required application components; 
9
‘‘(B) determine the extent to which the 
10
critical need antimicrobial meets the favored 
11
characteristics 
identified 
under 
section 
12
399OO(c)(2), and deny any application for a 
13
drug that meets none of such characteristics; 
14
and 
15
‘‘(C) assign a monetary value to the con-
16
tract based on the regulations developed under 
17
section 399OO(d). 
18
‘‘(b) CRITERIA.—To qualify for a subscription con-
19
tract under this section, the sponsor of an antimicrobial 
20
drug designated as a critical need antimicrobial shall agree 
21
to— 
22
‘‘(1) ensure commercial and Federal availability 
23
of the antimicrobial drug within 30 days of receiving 
24
20:39 Jul 22, 2021
H3932
19 
•HR 3932 IH
first payment under the contract, and sufficient sup-
1
ply for susceptibility device manufacturers; 
2
‘‘(2) identify, track, and publicly report drug 
3
resistance data and trends using available data re-
4
lated to the antimicrobial drug; 
5
‘‘(3) develop and implement education and com-
6
munications strategies, including communications 
7
for individuals with limited English proficiency and 
8
individuals with disabilities, for health care profes-
9
sionals and patients about appropriate use of the 
10
antimicrobial drug; 
11
‘‘(4) submit an appropriate use assessment to 
12
the Secretary, Committee, Food and Drug Adminis-
13
tration, and Centers for Disease Control and Pre-
14
vention every 2 years regarding use of the anti-
15
microbial drug, including how the drug is being mar-
16
keted; 
17
‘‘(5) submit a plan for registering the drug in 
18
additional countries where an unmet medical need 
19
exists; 
20
‘‘(6) ensure a reliable drug supply chain, where 
21
any interruption to the supply chain will not last for 
22
more than 60 days in the United States; 
23
20:39 Jul 22, 2021
H3932
20 
•HR 3932 IH
‘‘(7) complete any postmarketing studies re-
1
quired by the Food and Drug Administration in a 
2
timely manner; 
3
‘‘(8) produce the drug at a reasonable volume 
4
determined with the Secretary to ensure patient ac-
5
cess to the drug; 
6
‘‘(9) price the drug at a price that is not lower 
7
than a comparable generic drug; 
8
‘‘(10) abide by the manufacturing and environ-
9
mental best practices in the supply chain to ensure 
10
that there is no discharge into, or contamination of, 
11
the environment by antimicrobial agents or products 
12
as a result of the manufacturing process; and 
13
‘‘(11) abide by other terms as the Secretary 
14
may require. 
15
‘‘(c) AMOUNT AND TERMS OF CONTRACTS.— 
16
‘‘(1) AMOUNTS.—A subscription contract under 
17
this section shall be for the sale to the Secretary of 
18
any quantity of the antimicrobial drug needed over 
19
the term of the contract under paragraph (2), at an 
20
agreed upon price, for a total projected amount de-
21
termined by the Secretary that is not less than 
22
$750,000,000 and not more than $3,000,000,000, 
23
adjusted for inflation, accounting for the favored 
24
characteristics of the drug, as determined by the 
25
20:39 Jul 22, 2021
H3932
21 
•HR 3932 IH
Secretary, in consultation with the Committee, under 
1
subsection (a)(2), and shall be allocated from the 
2
amount made available under section 399SS(a). Not 
3
later than 6 months after the subscription contract 
4
is granted under subsection (a), the Secretary shall 
5
provide payments for purchased drugs in install-
6
ments established by the Secretary in consultation 
7
with the sponsor of the antimicrobial drug and in ac-
8
cordance with subsection (d)(3). Funds received by 
9
the sponsor shall be used to support criteria quali-
10
fication under subsection (b), the completion of post-
11
marketing clinical studies, manufacturing, other pre-
12
clinical and clinical activities, or other activities 
13
agreed to by the Secretary and sponsor in the con-
14
tract. 
15
‘‘(2) TERMS.— 
16
‘‘(A) INITIAL TERM.—The initial term of a 
17
contract under this subsection shall be no less 
18
than 5 years or greater than the greater of 10 
19
years or the remaining period of time during 
20
which the sponsor has patent protections or a 
21
remaining exclusivity period with respect to the 
22
antimicrobial drug in the United States, as list-
23
ed in the publication of the Food and Drug Ad-
24
ministration entitled ‘Approved Drug Products 
25
20:39 Jul 22, 2021
H3932
22 
•HR 3932 IH
with Therapeutic Equivalence Evaluations’. 
1
Payments may be in equal annual installments 
2
with the option to redeem 50 percent of the last 
3
year’s reimbursement in year 1 of the contract 
4
in order to offset costs of establishing manufac-
5
turing capacity, or another subscription ar-
6
rangement to which the Secretary and sponsor 
7
agree. Subscription contracts shall remain in ef-
8
fect for such period even if the infection treated 
9
by such antimicrobial drug is later removed 
10
from the list of infections under section 
11
399OO(c)(1). 
12
‘‘(B) EXTENSION
OF
CONTRACTS.—The 
13
Secretary may extend a subscription contract 
14
with a sponsor under this subsection beyond the 
15
initial contract period. A single contract exten-
16
sion may be in effect not later than the date on 
17
which all periods of exclusivity granted by the 
18
Food and Drug Administration expire and shall 
19
be in an amount not to exceed $25,000,000 per 
20
year. All other terms of an extended contract 
21
shall be the same as the terms of the initial 
22
contract. The total amount of funding used on 
23
such contract extensions shall be no more than 
24
20:39 Jul 22, 2021
H3932
23 
•HR 3932 IH
$1,000,000,000, and shall be allocated from the 
1
amount made available under section 399SS. 
2
‘‘(C) MODIFICATION OF CONTRACTS.—The 
3
Secretary or sponsor, 1 year after the start of 
4
the contract period under this subsection and 
5
every 2 years thereafter, may request a modi-
6
fication of the amount of the contract based on 
7
information that adjusts favored characteristics 
8
in section 399OO(c)(2). 
9
‘‘(3) ADJUSTMENT.—In the case of an anti-
10
microbial drug that received a transitional subscrip-
11
tion contract under section 399OO(f), the amount of 
12
a subscription contract for such drug under this sec-
13
tion shall be reduced by the amount of the transi-
14
tional subscription contract under such section 
15
399OO(f) for such drug. 
16
‘‘(4) CONTRACTS
FOR
GENERIC
AND
BIO-
17
SIMILAR
VERSIONS.—Notwithstanding any other 
18
provision in this part, the Secretary may award a 
19
subscription contract under this section to a manu-
20
facturer of a generic or biosimilar version of an anti-
21
microbial drug for which a subscription contract has 
22
been awarded under this section. Such contracts 
23
shall be awarded in accordance with a procedure, in-
24
20:39 Jul 22, 2021
H3932
24 
•HR 3932 IH
cluding for determining the terms and amounts of 
1
such contracts, established by the Secretary. 
2
‘‘(d) ANNUAL ANTIMICROBIAL DRUG SPONSOR REV-
3
ENUE LIMITATIONS.— 
4
‘‘(1) REPORTING REQUIREMENT.— 
5
‘‘(A) IN GENERAL.—Not later than a date 
6
determined appropriate by the Secretary fol-
7
lowing the end of each calendar year, and not 
8
earlier than 6 months after the end of each cal-
9
endar year, the head (or a designee of such 
10
head) of each Federal agency carrying out a 
11
specified government program shall, in accord-
12
ance with this paragraph, report to the Sub-
13
scription Contract Office established under sec-
14
tion 399OO(d)(3) the total prescription drug 
15
sales for each applicable antimicrobial drug 
16
under contract with respect to such program for 
17
such calendar year. 
18
‘‘(B) MEDICARE PART D PROGRAM.—For 
19
purposes of subparagraph (A), the Secretary 
20
shall report, for each applicable antimicrobial 
21
drug covered under part D of title XVIII of the 
22
Social Security Act, the product of— 
23
‘‘(i) the per-unit ingredient cost, as 
24
reported to the Secretary by prescription 
25
20:39 Jul 22, 2021
H3932
25 
•HR 3932 IH
drug plans and Medicare Advantage pre-
1
scription drug plans, minus any per-unit 
2
rebate, discount, or other price concession 
3
provided by the sponsor of such applicable 
4
antimicrobial drug, as reported to the Sec-
5
retary by the prescription drug plans and 
6
the Medicare Advantage prescription drug 
7
plans; and 
8
‘‘(ii) the number of units of such ap-
9
plicable antimicrobial drug paid for under 
10
such part D. 
11
‘‘(C) MEDICARE PART B PROGRAM.— 
12
‘‘(i) IN
GENERAL.—For purposes of 
13
subparagraph (A), the Secretary shall re-
14
port, for each applicable antimicrobial drug 
15
covered under part B of title XVIII of the 
16
Social Security Act, the product of— 
17
‘‘(I) the per-unit average sales 
18
price (as defined in section 1847A(c) 
19
of such Act) or the per-unit payment 
20
rate under such part B for a sepa-
21
rately paid prescription drug without 
22
a reported average sales price; and 
23
20:39 Jul 22, 2021
H3932
26 
•HR 3932 IH
‘‘(II) the number of units of such 
1
applicable antimicrobial drug paid for 
2
under such part B. 
3
‘‘(ii) 
UNITS
AND
ALLOCATED 
4
PRICES.—The Secretary shall establish a 
5
process for determining the units and the 
6
allocated price for purposes of this sub-
7
paragraph 
for 
those 
applicable 
anti-
8
microbial drugs that are not separately 
9
payable or for which National Drug Codes 
10
are not reported. 
11
‘‘(D) MEDICARE PART A PROGRAM.— 
12
‘‘(i) IN
GENERAL.—For purposes of 
13
subparagraph (A), the Secretary shall re-
14
port, for each applicable antimicrobial drug 
15
covered under part A of title XVIII of the 
16
Social Security Act, the product of— 
17
‘‘(I) the per-unit price under 
18
such part A for the antimicrobial 
19
drug; and 
20
‘‘(II) the number of units of such 
21
antimicrobial drug paid for under 
22
such part A. 
23
‘‘(ii) SPECIAL RULE.—For purposes of 
24
clause (i), the Secretary shall establish a 
25
20:39 Jul 22, 2021
H3932
27 
•HR 3932 IH
process for determining the units and the 
1
allocated price for those prescription drugs 
2
that are not separately payable or for 
3
which National Drug Codes are not re-
4
ported in the diagnosis-related groups. 
5
‘‘(E) MEDICAID PROGRAM.—Under the au-
6
thority of section 1902(a)(6) of the Social Secu-
7
rity Act, the Secretary shall require each State 
8
that makes medical assistance available under 
9
the State plan under title XIX of such Act (or 
10
any waiver of such plan) for an applicable anti-
11
microbial drug (including, if applicable, any 
12
such drug which is a covered outpatient drug 
13
under a rebate agreement entered into under 
14
section 1927 of such Act) to report, in a form 
15
consistent with a standard reporting format es-
16
tablished by the Secretary, not later than the 
17
date determined under subparagraph (A)— 
18
‘‘(i) information on the total number 
19
of units of each dosage form and strength 
20
and package size of each applicable anti-
21
microbial drug dispensed during the pre-
22
ceding calendar year under such State plan 
23
or waiver (including any such drugs dis-
24
pensed to an individual enrolled with a 
25
20:39 Jul 22, 2021
H3932
28 
•HR 3932 IH
medicaid managed care organization or 
1
other specified entity (as such terms are 
2
defined in section 1903(m) of such Act)); 
3
and 
4
‘‘(ii) with respect to each dosage form 
5
and strength and package size of each such 
6
drug, the amount equal to— 
7
‘‘(I) the product of— 
8
‘‘(aa) the total number of 
9
units dispensed under the State 
10
plan or waiver during the pre-
11
ceding calendar year (as deter-
12
mined under clause (i)); and 
13
‘‘(bb) the per-unit ingredient 
14
cost paid by the State for each 
15
such unit; minus 
16
‘‘(II) any discounts or other price 
17
concessions provided and rebates paid 
18
to the State with respect to the dos-
19
age form and strength and package 
20
size of such drug and such calendar 
21
year (including rebates paid under a 
22
rebate agreement under section 1927 
23
of such Act and any State supple-
24
20:39 Jul 22, 2021
H3932
29 
•HR 3932 IH
mental rebates paid under a supple-
1
mental rebate agreement). 
2
‘‘(F) DEPARTMENT
OF
VETERANS
AF-
3
FAIRS.—For purposes of subparagraph (A), the 
4
Secretary of Veterans Affairs shall report the 
5
total amount paid for each applicable anti-
6
microbial drug procured by the Veterans Health 
7
Administration for individuals who receive 
8
health care from the Administration. 
9
‘‘(G) DEPARTMENT
OF
DEFENSE
AND 
10
TRICARE PROGRAM.—For purposes of subpara-
11
graph (A), the Secretary of Defense shall report 
12
the sum of— 
13
‘‘(i) the total amount paid for each 
14
applicable antimicrobial drug procured by 
15
the Department of Defense for individuals 
16
who receive health care from the Depart-
17
ment; and 
18
‘‘(ii) for each applicable antimicrobial 
19
drug dispensed under the TRICARE retail 
20
pharmacy 
program 
under 
section 
21
1074g(a)(2)(E)(ii) of title 10, United 
22
States Code, the product of— 
23
‘‘(I) the per-unit ingredient cost, 
24
minus any per-unit rebate paid by the 
25
20:39 Jul 22, 2021
H3932
30 
•HR 3932 IH
sponsor of the applicable antimicrobial 
1
drug; and 
2
‘‘(II) the number of units of such 
3
applicable antimicrobial drug dis-
4
pensed under such program. 
5
‘‘(H) DEPARTMENT OF HOMELAND SECU-
6
RITY.—For purposes of subparagraph (A), the 
7
Secretary of Homeland Security shall report the 
8
total amount paid for each applicable anti-
9
microbial drug procured by the Department of 
10
Homeland Security for individuals who receive 
11
health care through a program carried out by 
12
the Department. 
13
‘‘(I) BUREAU OF PRISONS.—For purposes 
14
of subparagraph (A), the Director of the Bu-
15
reau of Prisons shall report the total amount 
16
paid for each applicable antimicrobial drug pro-
17
cured by the Bureau of Prisons for individuals 
18
who receive health care through the Bureau. 
19
‘‘(J) INDIAN HEALTH SERVICE.—For pur-
20
poses of subparagraph (A), the Secretary, act-
21
ing through the Indian Health Service, shall re-
22
port the total amount paid for each applicable 
23
antimicrobial drug procured by the Service for 
24
20:39 Jul 22, 2021
H3932
31 
•HR 3932 IH
individuals who receive health care through the 
1
Service. 
2
‘‘(2) REGULATIONS.—Not later than 1 year 
3
after the date of enactment of this part, the Sec-
4
retary, in consultation with the heads of Federal 
5
agencies carrying out specified government pro-
6
grams, shall issue regulations to assist such heads 
7
(or their designees) in carrying out the requirements 
8
under this section. 
9
‘‘(3) SUBSCRIPTION CONTRACT ADJUSTMENT.— 
10
Pursuant to the contract entered into under this sec-
11
tion with respect to an applicable antimicrobial drug, 
12
for each year of the term of such contract, the Sec-
13
retary shall, not earlier than 6 months after the end 
14
of each calendar year, subtract from the payment in-
15
stallments determined for such contract under sub-
16
section (c)(1) for such year the revenue of the spon-
17
sor of such drug from the previous year from sales 
18
of the applicable antimicrobial drug reported under 
19
paragraph (1) for specified government programs. 
20
‘‘(4) DEFINITIONS.—In this subsection: 
21
‘‘(A) 
APPLICABLE
ANTIMICROBIAL 
22
DRUG.—The 
term 
‘applicable 
antimicrobial 
23
drug’ means an antimicrobial drug for which 
24
20:39 Jul 22, 2021
H3932
32 
•HR 3932 IH
the sponsor of such drug receives a subscription 
1
contract under subsection (a). 
2
‘‘(B) 
SPECIFIED
GOVERNMENT
PRO-
3
GRAM.—The term ‘specified government pro-
4
gram’ means— 
5
‘‘(i) the Medicare part D program 
6
under part D of title XVIII of the Social 
7
Security Act; 
8
‘‘(ii) the Medicare Part B program 
9
under part B of such title XVIII; 
10
‘‘(iii) the Medicare Part A program 
11
under part A of such title XVIII; 
12
‘‘(iv) the Medicaid program estab-
13
lished under title XIX of the Social Secu-
14
rity Act and includes, with respect to a 
15
State, any waiver in effect with respect to 
16
such program; 
17
‘‘(v) any program under which pre-
18
scription drugs are procured by the De-
19
partment of Veterans Affairs; 
20
‘‘(vi) any program under which pre-
21
scription drugs are procured by the De-
22
partment of Defense; 
23
20:39 Jul 22, 2021
H3932
33 
•HR 3932 IH
‘‘(vii) the TRICARE retail pharmacy 
1
program under section 1074g(a)(2)(E)(ii) 
2
of title 10, United States Code; 
3
‘‘(viii) any program under which pre-
4
scription drugs are procured by the De-
5
partment of Homeland Security; 
6
‘‘(ix) any program under which pre-
7
scription drugs are procured by the Bu-
8
reau of Prisons; or 
9
‘‘(x) any program under which pre-
10
scription drugs are procured by the Indian 
11
Health Service. 
12
‘‘(e) FAILURE TO ADHERE TO TERMS.—The Sec-
13
retary shall cease any payment installments under a con-
14
tract under this section if— 
15
‘‘(1) the sponsor— 
16
‘‘(A) permanently withdraws the anti-
17
microbial drug from the market in the United 
18
States; 
19
‘‘(B) fails to meet criteria under subsection 
20
(b); or 
21
‘‘(C) does not complete a postmarket study 
22
required by the Food and Drug Administration 
23
during the length of the term of the contract; 
24
20:39 Jul 22, 2021
H3932
34 
•HR 3932 IH
‘‘(2) the annual international and private insur-
1
ance market revenues with respect to an anti-
2
microbial drug (not counting any subscription reve-
3
nues from any source pursuant to a contract under 
4
this section or other international or private entities) 
5
exceed 5 times the average annual amount of the 
6
subscription contract paid by the Secretary as cer-
7
tified by the sponsor annually; or 
8
‘‘(3) if the total revenue of the sponsor from 
9
specified government programs, as defined in sub-
10
section (d)(4), for a year exceeds the amount of the 
11
subscription contract paid by the Secretary for that 
12
year. 
13
‘‘(f) PRIVATE PAYER AND INTERNATIONAL PAYER 
14
PARTICIPATION.—The Secretary shall make efforts to in-
15
crease the participation of domestic private payors and 
16
international payors in subscription contracts or other 
17
types of value-based arrangements that are similar to the 
18
subscription contracts authorized under this section. 
19
‘‘SEC. 399RR. ENCOURAGING APPROPRIATE USE OF ANTI-
20
BIOTICS AND COMBATING RESISTANCE. 
21
‘‘(a) ESTABLISHMENT OF HOSPITAL GRANT PRO-
22
GRAM.— 
23
‘‘(1) IN GENERAL.—Not later than 1 year after 
24
the date of enactment of this part, the Secretary and 
25
20:39 Jul 22, 2021
H3932
35 
•HR 3932 IH
the Director of the Centers for Disease Control and 
1
Prevention shall coordinate with the Administrator 
2
of the Health Resources and Services Administra-
3
tion, the Administrator of the Centers for Medicare 
4
& Medicaid Services, the National Coordinator for 
5
Health Information Technology, and other relevant 
6
agencies, to establish a grant program under the 
7
Centers for Disease Control and Prevention to sup-
8
port hospital and other inpatient facility efforts— 
9
‘‘(A) to judiciously use antimicrobial drugs, 
10
such as by establishing or implementing appro-
11
priate use programs, including infectious dis-
12
ease telehealth programs, using appropriate di-
13
agnostic tools, partnering with academic hos-
14
pitals, increasing health care-associated infec-
15
tion reporting, and monitoring antimicrobial re-
16
sistance; and 
17
‘‘(B) to participate in the National 
18
Healthcare Safety Network Antimicrobial Use 
19
and Resistance Module or the Emerging Infec-
20
tions Program Healthcare-Associated Infections 
21
Community Interface activity of the Centers for 
22
Disease Control and Prevention or a similar re-
23
porting program, as specified by the Secretary, 
24
relating to antimicrobial drugs. 
25
20:39 Jul 22, 2021
H3932
36 
•HR 3932 IH
‘‘(2) PRIORITIZATION.—In awarding grants 
1
under paragraph (1), the Secretary shall prioritize 
2
hospitals without an existing program to judiciously 
3
use antimicrobial drugs, subsection (d) hospitals (as 
4
defined in subparagraph (B) of section 1886(d)(2) 
5
of the Social Security Act that are located in rural 
6
areas (as defined in subparagraph (D) of such sec-
7
tion), critical access hospitals (as defined in section 
8
1861(mm)(1) of such Act), hospitals serving Tribal- 
9
populations, and safety-net hospitals. 
10
‘‘(3) FUNDING.—Of the amounts appropriated 
11
under section 399SS, the Secretary shall reserve 
12
$500,000,000 to carry out this subsection. 
13
‘‘(b) SURVEILLANCE AND REPORTING OF ANTIBIOTIC 
14
USE AND RESISTANCE.— 
15
‘‘(1) IN
GENERAL.—The Secretary, acting 
16
through the Director of the Centers for Disease 
17
Control and Prevention, shall use the National 
18
Healthcare Safety Network and other appropriate 
19
surveillance systems to assess— 
20
‘‘(A) appropriate conditions, outcomes, and 
21
measures causally related to antibacterial resist-
22
ance, including types of infections, the causes 
23
for infections, and whether infections are ac-
24
quired in a community or hospital setting, in-
25
20:39 Jul 22, 2021
H3932
37 
•HR 3932 IH
creased lengths of hospital stay, increased costs, 
1
and rates of mortality; and 
2
‘‘(B) changes in bacterial resistance to 
3
antimicrobial drugs in relation to patient out-
4
comes, including changes in percent resistance, 
5
prevalence of antibiotic-resistant infections, and 
6
other such changes. 
7
‘‘(2) ANTIBIOTIC
USE
DATA.—The Secretary, 
8
acting through the Director of the Centers for Dis-
9
ease Control and Prevention, shall work with Fed-
10
eral agencies (including the Department of Veterans 
11
Affairs, the Department of Defense, the Department 
12
of Homeland Security, the Bureau of Prisons, the 
13
Indian Health Service, and the Centers for Medicare 
14
& Medicaid Services), private vendors, health care 
15
organizations, pharmacy benefit managers, and 
16
other entities as appropriate to obtain reliable and 
17
comparable human antibiotic drug consumption data 
18
(including, as available and appropriate, volume an-
19
tibiotic distribution data and antibiotic use data, in-
20
cluding prescription data) by State or metropolitan 
21
areas. 
22
‘‘(3) ANTIBIOTIC RESISTANCE TREND DATA.— 
23
The Secretary, acting through the Director of the 
24
Centers for Disease Control and Prevention, shall in-
25
20:39 Jul 22, 2021
H3932
38 
•HR 3932 IH
tensify and expand efforts to collect antibiotic resist-
1
ance data and encourage adoption of the Antibiotic 
2
Use and Resistance Module within the National 
3
Healthcare Safety Network among all health care fa-
4
cilities across the continuum of care, including, as 
5
appropriate, acute care hospitals, dialysis facilities, 
6
nursing homes, ambulatory surgical centers, and 
7
other ambulatory health care settings in which anti-
8
microbial drugs are routinely prescribed. The Sec-
9
retary shall seek to collect such data from electronic 
10
medication administration reports and laboratory 
11
systems to produce the reports described in para-
12
graph (4). 
13
‘‘(4) PUBLIC
AVAILABILITY
OF
DATA.—The 
14
Secretary, acting through the Director of the Cen-
15
ters for Disease Control and Prevention, shall, for 
16
the purposes of improving the monitoring of impor-
17
tant trends in patient outcomes in relation to anti-
18
bacterial resistance— 
19
‘‘(A) make the data derived from surveil-
20
lance under this subsection publicly available 
21
through reports issued on a regular basis that 
22
is not less than annually; and 
23
‘‘(B) examine opportunities to make such 
24
data available in near real time. 
25
20:39 Jul 22, 2021
H3932
39 
•HR 3932 IH
‘‘SEC. 399SS. APPROPRIATIONS. 
1
‘‘(a) IN GENERAL.—To carry out this part, there are 
2
hereby appropriated to the Secretary, out of amounts in 
3
the 
Treasury 
not 
otherwise 
appropriated, 
4
$11,000,000,000, for fiscal year 2022, to remain available 
5
until expended. 
6
‘‘(b) EMERGENCY DESIGNATION.— 
7
‘‘(1) IN GENERAL.—The amounts provided by 
8
this section are designated as an emergency require-
9
ment pursuant to section 4(g) of the Statutory Pay- 
10
As-You-Go Act of 2010. 
11
‘‘(2) DESIGNATION IN SENATE.—In the Senate, 
12
this section is designated as an emergency require-
13
ment pursuant to section 4112(a) of H. Con. Res. 
14
71 (115th Congress), the concurrent resolution on 
15
the budget for fiscal year 2018. 
16
‘‘SEC. 399TT. STUDIES AND REPORTS. 
17
‘‘(a) IN GENERAL.—Not later than 6 years after the 
18
date of enactment of this part, the Comptroller General 
19
of the United States shall complete a study on the effec-
20
tiveness of this part in developing priority antimicrobial 
21
drugs. Such study shall examine the indications for, usage 
22
of, development of resistance with respect to, and private 
23
and societal value of critical need antimicrobial drugs, and 
24
the impact of the programs under this part on patients 
25
and markets of critical need antimicrobial drugs. The 
26
20:39 Jul 22, 2021
H3932
40 
•HR 3932 IH
Comptroller General shall report to the Committee on 
1
Health, Education, Labor, and Pensions of the Senate and 
2
the Committee on Energy and Commerce of the House 
3
of Representatives on the findings of such study. 
4
‘‘(b) ANTIBIOTIC USE IN THE UNITED STATES; AN-
5
NUAL REPORTS.—The Director of the Centers for Disease 
6
Control and Prevention shall, each year, update the report 
7
entitled ‘Antibiotic Use in the United States’ to include 
8
updated information on progress and opportunities with 
9
respect to data, programs, and resources for prescribers 
10
to promote appropriate use of antimicrobial drugs. 
11
‘‘(c) REPORT ON ANTIMICROBIAL PROPHYLACTICS.— 
12
Not later than 3 years after the date of enactment of this 
13
part, the Director of the Centers for Disease Control and 
14
Prevention shall publish a report on antimicrobial prophy-
15
lactics. 
16
‘‘SEC. 399UU. DEFINITIONS. 
17
‘‘In this part— 
18
‘‘(1) the term ‘antimicrobial drug’— 
19
‘‘(A) means, subject to subparagraph (B), 
20
a product that is— 
21
‘‘(i) a drug that directly inhibits rep-
22
lication of or kills bacteria or fungi rel-
23
evant to the proposed indication at con-
24
centrations likely to be attainable in hu-
25
20:39 Jul 22, 2021
H3932
41 
•HR 3932 IH
mans to achieve the intended therapeutic 
1
effect; or 
2
‘‘(ii) a biological product that acts di-
3
rectly on bacteria or fungi or on the sub-
4
stances produced by such bacteria or fungi; 
5
and 
6
‘‘(B) does not include— 
7
‘‘(i) a drug that achieves the effect de-
8
scribed by subparagraph (A)(i) only at a 
9
concentration that cannot reasonably be 
10
studied in humans because of its antici-
11
pated toxicity; or 
12
‘‘(ii) a vaccine; and 
13
‘‘(2) the term ‘Committee’ means the Com-
14
mittee on Critical Need Antimicrobials established 
15
under section 399OO.’’. 
16
Æ 
20:39 Jul 22, 2021
H3932
